Viral Vector And Plasmid DNA Manufacturing Market To Reach $19.52 Billion By 2033

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends

The global viral vector and plasmid DNA manufacturing market size is expected to reach USD 19.52 billion by 2033, registering a CAGR of 14.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

 Request a free sample copy or view report summary: Viral Vector And Plasmid DNA Manufacturing Market Report

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights

• By vector type, the adeno-associated virus (AAV) segment held the largest market share in 2025. The lentivirus segment is expected to grow at a significant CAGR over the forecast period.

• By application, the vaccinology segment held the highest share of 22.08% in 2025. The cell therapy segment is expected to grow at the fastest CAGR over the forecast period.

• By end-use, the research institute segment held the largest revenue share in 2025. The pharmaceutical and biotechnology companies segment is expected to grow significantly over the forecast period.

• By workflow, the downstream processing segment dominated the market, accounting for the largest revenue share in 2025. The upstream processing segment is expected to grow at a significant CAGR over the forecast period.

• By disease, the cancer segment dominated the market, accounting for the largest share of 38.03% in 2025. Genetic disorders are expected to register a significant CAGR during the forecast period.

• North America viral vector and plasmid DNA manufacturing market held the largest share of 48.98% of the global market in 2025. The viral vector and plasmid DNA manufacturing industry in the U.S. is expected to grow significantly over the forecast period.

Viral Vector And Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented global viral vector and plasmid DNA manufacturing market report based on vector type, workflow, application, end-use, disease, and region:

Viral Vector And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Adeno-associated virus (AAV)

• Lentivirus

• Adenovirus

• Retrovirus

• Plasmids

• Others

Viral Vector And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Billion, 2021 - 2033)

• Upstream Manufacturing

  • Vector Amplification & Expansion

  • Vector Recovery/Harvesting

• Downstream Manufacturing

  • Purification

  • Fill Finish

Viral Vector And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Billion, 2021 - 2033)

• Antisense & RNAi Therapy

• Gene Therapy

• Cell Therapy

• Vaccinology

• Research Applications

Viral Vector And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Billion, 2021 - 2033)

• Pharmaceutical and Biopharmaceutical Companies

• Research Institutes

Viral Vector And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Billion, 2021 - 2033)

• Cancer

• Genetic Disorders

• Infectious Diseases

• Others

Viral Vector And Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Kuwait

  • UAE

  • South Africa

  • Saudi Arabia

List of Key Players of Viral Vector And Plasmid DNA Manufacturing Market

• Merck KGaA

• Lonza

• FUJIFILM Diosynth Biotechnologies

• Thermo Fisher Scientific

• Cobra Biologics

• Catalent Inc.

• Wuxi Biologics

• Takara Bio Inc.

• Waisman Biomanufacturing

• Genezen laboratories

• Batavia Biosciences

• Miltenyi Biotec GmbH

• SIRION Biotech GmbH

• Virovek Incorporation

• BioNTech IMFS GmbH

• Audentes Therapeutics

• BioMarin Pharmaceutical

• RegenxBio, Inc.